Efimosfermin alfa
Protein / enzyme therapeutic
Also known as GSK6519754
Evidence outlook · registrational
MASH / NASH: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2028-03-24.
NCT04880031: The study was randomized and double-blind with placebo control in its main comparative parts; Part B randomized 84 participants with biopsy-confirmed MASH and F2 or F3 fibrosis to efimosfermin or placebo for 24 weeks. Its registered primary outcomes were safety and tolerability measures (adverse events, blood pressure, heart rate and grade 3 or 4 laboratory abnormalities), so there is no efficacy comparison to call. The peer-reviewed Part B report (The Lancet 2026) found efimosfermin generally well tolerated, with no clinically meaningful vital-sign changes and no clinically significant grade 3 or higher laboratory abnormalities.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ZENITH-1 NCT07221227 · Non-alcoholic Fatty Liver Disease Registry: NCT07221227 | 3 | Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52; Proportion of participants experiencing resolution of steatohepatitis reading and no worsening of MASH CRN fibrosis score at Week 52; Time from randomization to an adjudicated composite liver-related clinical outcome (From Randomization (Day 1) to 48 months) 2028-03-29 | In progress: results expected 29 Mar 2028 | not yet graded | link ↗ |
View 4 more trials
NEBULA-1 NCT07701993 · Metabolic Dysfunction-associated Steatohepatitis Registry: NCT07701993 | 3 | Time from randomization to an adjudicated composite liver-related clinical outcome (From Randomization (Day 1) to Week 356 (end of treatment)) 2033-06-23 | In progress: results expected 23 Jun 2033 | not yet graded | link ↗ |
ZENITH-2 NCT07221188 · Non-alcoholic Fatty Liver Disease Registry: NCT07221188 | 3 | Number of participants with treatment-emergent adverse events (TEAEs) and TEAEs by severity (At Week 52); Number of participants with TEAEs leading to discontinuation and TEAEs leading to discontinuation by severity (At Week 52); Number of participants with Grade 3 and Grade 4 laboratory abnormalities (At Week 52) 2028-03-24 | In progress: results expected 24 Mar 2028 | not yet graded | link ↗ |
NEBULA-2 NCT07704892 · Metabolic Dysfunction-associated Steatohepatitis Registry: NCT07704892 | 3 | Part A: Proportion of participants achieving improvement in liver fibrosis by >=1 stage and no worsening of MASH (At Week 96) 2030-10-16 | In progress: results expected 16 Oct 2030 | not yet graded | link ↗ |
NCT04880031 NCT04880031 · Nonalcoholic Steatohepatitis (NASH) The study was randomized and double-blind with placebo control in its main comparative parts; Part B randomized 84 participants with biopsy-confirmed MASH and F2 or F3 fibrosis to efimosfermin or placebo for 24 weeks. Its registered primary outcomes were safety and tolerability measures (adverse events, blood pressure, heart rate and grade 3 or 4 laboratory abnormalities), so there is no efficacy comparison to call. The peer-reviewed Part B report (The Lancet 2026) found efimosfermin generally well tolerated, with no clinically meaningful vital-sign changes and no clinically significant grade 3 or higher laboratory abnormalities. Registry: NCT04880031 | 2 | Part A, Part B, Part C, and Part D: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) (Until End of study/Early Termination (Day 393)); Part A, Part B, Part C, and Part D: Changes from Baseline in systolic and diastolic blood pressure (BP) (Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)); Part A, Part B, Part C, and Part D: Changes from Baseline in heart rate (Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)); Part A, Part B, Part C, and Part D: Number of participants with Grade 3 and Grade 4 laboratory abnormalities (Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)) 2025-10-27 | Part B (24 weeks, MASH with F2 or F3 fibrosis): adverse events in 29 of 43 (67%) on efimosfermin 300 mg every 4 weeks vs 22 of 40 (55%) on placebo, mostly mild or moderate and mainly transient gastrointestinal events; no clinically meaningful vital-sign changes, no clinically significant grade 3 or higher laboratory abnormalities, no deaths and no adverse events above grade 3. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other FGF21 receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for MASH / NASH: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Efimosfermin Alfa: this drug | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | Weak signal | Featured results are safety only in this race | |
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT03900429: Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). | |
| Semaglutide (Wegovy) | Approved | Peptide | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | not yet graded | No reviewed efficacy summary in this indication | |
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | not yet graded | No reviewed efficacy summary in this indication | |
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT05989711: Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). | |
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | Reliable signal | NCT06309992: Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. | |
| Belapectin | Phase 2/3 | Polysaccharide | Galectin-3 | Partial signal | NCT04365868: Proportion of patients with new esophageal varices at 78 weeks (registry): belapectin 2 mg/kg 45/119, belapectin 4 mg/kg 51/118 vs placebo 56/118. The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population (n=355); in the pre-defined per-protocol population (n=290), the 2 mg/kg group showed a 48.9% reduction in varices (p<0.05). missed NCT02421094: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) (16 weeks): GR-MD-02 8 mg/kg 19.15 milliseconds (ms) (95% CI -7.7 to 43.5) vs Placebo 1.25 milliseconds (ms) (95% CI -7.7 to 43.5) missed | |
| ALG-055009 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-PNP | Phase 2 | RNA / oligonucleotide | PNPLA3 | Weak signal | No reviewed efficacy summary in this indication | |
| Denifanstat | Phase 2 | Small molecule | Fatty acid synthase (FASN), FASN | Reliable signal | NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45 NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021). | |
| ECC4703 | Phase 2 | — | Thyroid hormone receptor beta (THRβ) | not yet graded | No reviewed efficacy summary in this indication | |
| Efinopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Efocipegtrutide | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | not yet graded | No reviewed efficacy summary in this indication | |
| Ervogastat | Phase 2 | Small molecule | Diacylglycerol acyltransferase 2 (DGAT2) | Partial signal | NCT04321031: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) (Week 48): DGAT2i/PF-06865571 25 mg BID 45% (95% CI 38% to 53%) | DGAT2i/PF-06865571 75 mg BID 48% (95% CI 42% to 55%) | DGAT2i/PF-06865571 150 mg BID 50% (95% CI 43% to 57%) | DGAT2i/PF-06865571 300 mg BID 51% (95% CI 43% to 59%) vs Placebo 38% (95% CI 26% to 50%) NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Gatuzosiran | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | NCT06104319: Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg) NCT04202354: Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo. | |
| HU6 | Phase 2 | Small molecule | Mitochondrial uncoupling | not yet graded | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2 | Small molecule | Glucocorticoid receptor | Weak signal | NCT05117489: Open-label study in patients with presumed non-alcoholic steatohepatitis: patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease. | |
| Namodenoson | Phase 2 | — | Adenosine A3 receptor | Partial signal | NCT02927314: Change from baseline in serum ALT at Week 12, namodenoson 25 mg b.d. vs placebo: P=0.066 (trend, not statistically significant) missed | |
| ORMD-0801 | Phase 2 | Peptide | Insulin | not yet graded | No reviewed efficacy summary in this indication | |
| Rapirosiran (ALN-HSD) | Phase 2 | RNA / oligonucleotide | HSD17B13 | Weak signal | Featured results are safety only in this race | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | not yet graded | No reviewed efficacy summary in this indication | |
| Vanoglipel | Phase 2 | Small molecule | GPR119 | not yet graded | No reviewed efficacy summary in this indication | |
| VK2809 | Phase 2 | Small molecule | Thyroid hormone receptor-beta | Partial signal | NCT04173065: Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only). NCT02927184: Primary endpoint, placebo-adjusted % change in LDL-C at week 12: VK2809 10mg every-other-day -23.6% (p=0.0121); VK2809 10mg daily -20.2% (p=0.0269); combined VK2809 -21.8% (p=0.0061). | |
| Vonafexor | Phase 2 | Small molecule | Farnesoid X receptor (FXR/NR1H4) | Partial signal | NCT03812029: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (12 weeks): Vonafexor 100 mg QD Part B -6.3% (95% CI -8.1 to -4.5) | Vonafexor 200 mg QD Part B -5.4% (95% CI -7.2 to -3.6) vs Placebo Part B -2.3% (95% CI -4 to -0.6) | Placebo Part A 3.9% (95% CI -2.5 to 10.4) | |
| Zabopegdutide | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | Partial signal | NCT06410924: Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. | |
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-PNPLA3 | Phase 1(overall) | RNA / oligonucleotide | PNPLA3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD2389 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3006337 | Phase 1 | — | — | Weak signal | Featured results are safety only in this race | |
| BI 3804379 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| ISH0688 | Phase 1(overall) | Protein / enzyme therapeutic | FGF21 receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ZT003 | Phase 1(overall) | Peptide | FGF21/GLP-1 receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| MGL-2086 | —(overall) | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| NNC4005-001 | —(overall) | RNA / oligonucleotide | SLC25A5 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7503 | Discontinued | RNA / oligonucleotide | HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNA | Weak signal | No reviewed efficacy summary in this indication | |
| Clesacostat | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) | Partial signal | NCT04321031: Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model (Week 48): DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID 23/35 | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID 19/30 vs Placebo 13/34 | DGAT2i/PF-06865571 25 mg BID 16/35 | DGAT2i/PF-06865571 75 mg BID 25/48 | DGAT2i/PF-06865571 150 mg BID 21/42 | DGAT2i/PF-06865571 300 mg BID 14/31 NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Obeticholic Acid (Ocaliva) | Discontinued | — | FXR | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05221304 + PF-06865571 | Discontinued | Small molecule | Acetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2 | Partial signal | NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89) | |
| Rosiglitazone (Avandia) | Discontinued | Small molecule | PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Efimosfermin alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.